Effective January 1, 2017 - New permanent J-code for ONIVYDE: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-MACK (6225)

Designed For Prolonged Exposure1,2

ONIVYDE® (irinotecan liposome injection) is a novel encapsulation of irinotecan in a long-circulating liposome

  • The half-life (T1/2) of total irinotecan following administration of ONIVYDE 70 mg/m2 is 25.8 hours
  • 95% of irinotecan remains liposome encapsulated for up to 169.5 hours following administration
    • T1/2 of total SN-38 (an active form of irinotecan) following administration of ONIVYDE is 67.8 hours
  • In mice bearing human tumor xenografts, ONIVYDE achieved similar intratumoral exposure of SN-38 at a 5-fold lower dose than irinotecan HCl
ONIVYDE® (irinotecan liposome injection)

HCl=hydrochloride; PEG-DSPE=polyethylene glycol-distearoylphosphatidylethanolamine.

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

References: 1. ONIVYDE [package insert]. Cambridge, MA. Merrimack Pharmaceuticals, Inc.; October 2015. 2. Data on file. Merrimack Pharmaceuticals, Inc.; Cambridge, MA.

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION